Stirlescent®

250mg naproxen effervescent tablets

Adverse events should be reported
Reporting forms and information can be found at yellowcard.mhra.gov.uk or downloaded from Google Play or the Apple App Store.
Adverse events should also be reported to JensonR+ on 01271 314 320 or Stirling Anglian Pharmaceuticals on 0345 527 0680.

Information for Healthcare Professionals

The licensed indication for Stirlescent® is for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in patients aged 18 years or over with a creatinine clearance of at least 30 ml/min. Contraindicated in patients with moderate or severe renal impairment.

Stirlescent® offers a lower cost option for treatment with naproxen in patients who may experience swallowing difficulties and who require a liquid form of NSAID.

Stirlescent® is used to treat adults only.

Stirlescent® is the only effervescent naproxen available in the UK.

Stirlescent
Stirlescent

Stirlescent®: A clear solution!

  • For patients that don’t like tablets or can’t swallow tablets
  • For patients that prefer to dissolve their tablets in water
  • A solution when you need to advise patients not to crush their tablets
  • A solution for when your patient askes you not to prescribe them a syrup

How to take Stirlescent®

One to Two tablets dissolved in 150ml of water
One to Two tablets dissolved in 150ml of water
Three tablets dissolved in 300ml water
Three tablets dissolved in 300ml water
To be taken preferably with, or after, food
To be taken preferably with, or after, food

Stirlescent® availability

  • Legal category: POM
  • EU manufactured
  • The only licensed naproxen effervescent on the market
  • 3 year shelf life
  • Blackcurrant flavour
  • NHS list price: £52.72 (20)
  • Exclusively stocked and available through Alliance Healthcare, AAH and Phoenix Medical Supplies.

Healthcare Professional leaflets

Stirlescent For Healthcare Professionals
Stirlescent For Healthcare Professionals

Adverse events should be reported
Reporting forms and information can be found at yellowcard.mhra.gov.uk or downloaded from Google Play or the Apple App Store.
Adverse events should also be reported to JensonR+ on 01271 314 320 or Stirling Anglian Pharmaceuticals on 0345 527 0680.

Stirlescent® – Information for Healthcare Professionals
This website uses cookies to improve your experience.
Privacy Policy